AWM
KYMR icon

Avior Wealth Management’s Kymera Therapeutics KYMR Stock Holding History

Avior Wealth Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$321 – 3044
2024
Q1 		$321 Buy
+8
New +$286 ﹤0.01% 2703

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Avior Wealth Management's KYMR Position: Q2 2024 in Review

Avior Wealth Management sold out of Kymera Therapeutics (KYMR) in Q2 2024, closing a stake of 8 shares — an estimated $321 sold.

Avior Wealth Management first reported a position in KYMR in Q1 2024 and held it in 1 quarter. The position peaked at $321 in Q1 2024. 157 funds tracked by Wall St. Rank hold KYMR as of Q2 2024.

  • Avior Wealth Management reported no remaining Kymera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 8 Kymera Therapeutics shares in Q2 2024, an estimated $321.
  • Avior Wealth Management first reported a position in Kymera Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Kymera Therapeutics position peaked at $321 in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.